Decitabine

Nature Reviews Drug Discovery

Volumn 5, Issue 11, 2006, Pages 891-892

  Gore, Steven D ^a   Jones, Carole ^b   Kirkpatrick, Peter ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b IQVIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CHELATING AGENT; CYTARABINE; DEFERASIROX; DNA; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; NUCLEOSIDE ANALOG; PROTEIN P15;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL TRIAL; DNA METHYLATION; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; UNITED STATES;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DRUG APPROVAL; HUMANS; MYELODYSPLASTIC SYNDROMES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33750524236     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2180     Document Type: Article

References (19)

1. Heaney, M. L. & Golde, D. W. Myelodysplasia. N. Engl. J. Med. 340, 1649-1660 (1999).
2. Silverman, L. R. & Mufti, G. J. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nature Clin. Pract. Oncol. 2, S12-S23 (2005).
3. Issa, J.-P. J., Kantarjian, H. M. & Kirkpatrick, P. Azacitidine. Nature Rev. Drug Discov. 4, 275-276 (2005).
4. Baylin, S. B. DNA methylation and cancer. Nature Clin. Pract. Oncol. 2, S4-S11 (2005).
5. Jones, P. A. & Taylor, S. M. Cellular differentiation, cytidine analogues and DNA methylation. Cell 20, 85-93 (1980).
6. Charache, S. et al. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta globin gene complex. Proc. Natl Acad. Sci. USA 80, 4842-4846 (1983).
7. Daskalakis, M. et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100, 2957-2964 (2002).
8. FDA labelling information [online], (2006).
9. Kantarjian, H. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a Phase III randomized study. Cancer 106, 1794-1803 (2006).
10. Wijermans, P. et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J. Clin. Oncol. 18, 956-962 (2000).
11. List, A. et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352, 549-557 (2005).
12. Silverman, L. R. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J. Clin. Oncol. 20, 2429-2440 (2002).
13. Kornblith, A. B. et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J. Clin. Oncol. 20, 2441-2452 (2002).
14. Gore, S. D. et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66, 6361-6369 (2006).
15. Kantarjian, H. et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1 Aug 2006 (doi: blood-2006-05-021162v1).
16. Garcia-Manero, G. et al. Phase I/II study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 1 Aug 2006 (doi: Blood-2006-03-009142v1).
17. Cameron, E. E. et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 21, 103-107 (1999).
18. Myelodysplastic Syndromes: Basic Explanations 1-19 (Aplastic Anemia & MDS International Foundation, Annapolis, Maryland, 2005).
19. IMS Health, IMS MIDAS MAT (June 2006).